In 131 patients with BCR::ABL1IS > 0.1% after 2 years of TKI therapy, patients with levels >0.1%–1% or >1%–10%, had 10-year CML-specific survival rates of >90%. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.